The effects of taprostene, a synthetic prostacyclin analogue, were investigated in a 6-hour model of myocardial ischemia (MI) with reperfusion in anesthetized cats. Taprostene (100 ng/ kg/min) was infused intravenously starting 30 minutes postocclusion of the left anterior descending coronary artery followed by reperfusion 1 hour later, and the cats were observed for an additional 4.5 hours. Taprostene infusion resulted in significantly lower plasma creatine phosphokinase activities at every time from 3 to 6 hours for the MI+taprostene group compared with the MI+vehicle group and were not significantly different when compared with sham MI controls. The areas at risk, expressed as a percentage of the total left ventricular weights, were not significantly different between the MI groups. However, the necrotic area expressed as a percentage of the myocardial area at risk was significantly lower in the taprostene-treated cats compared with the untreated MI group (p<0.01). Cardiac myeloperoxidase activities indicated that significantly fewer neutrophils were attracted to the area at risk and to the ischemic zone of the MI+taprostene cats when compared with the MI cats given only the vehicle. Data from isolated left anterior descending coronary artery ring preparations removed from hearts after 6 hours of ischemia indicated that the endothelium was damaged by ischemia-reperfusion injury in the untreated cats. However, endothelial dysfunction was not observed in circumflex coronary arteries of ischemic cats or in coronary rings isolated from MI+taprostene cats. Thus, taprostene exerted a significant cardioprotection in cats subjected to ischemia and reperfusion. This cardioprotection appears to be related to protection of coronary endothelium integrity and prevention of neutrophil accumulation in the ischemic myocardium. (Circulation Research 1990;66:1362-1370 P rostacyclin (PGI2) is a major product of the metabolism of arachidonic acid produced by the vascular endothelium. PGI2 has a profile of cardiovascular effects that include systemic hypotension and coronary vasodilation.1,2 In addition to these hemodynamic effects, PGI2 also has cytoprotective actions such as antiaggregatory actions on platelets,2 and stabilization of erythrocyte3 and lysosomal membranes.14 As a result of this profile of effects, PGI2 has been shown to be beneficial in a variety of models of ischemia and shock.4 In partic-
P rostacyclin (PGI2) is a major product of the metabolism of arachidonic acid produced by the vascular endothelium. PGI2 has a profile of cardiovascular effects that include systemic hypotension and coronary vasodilation.1,2 In addition to these hemodynamic effects, PGI2 also has cytoprotective actions such as antiaggregatory actions on platelets,2 and stabilization of erythrocyte3 and lysosomal membranes.14 As a result of this profile of effects, PGI2 has been shown to be beneficial in a variety of models of ischemia and shock.4 In partic-15 -cyclohexyl- 16, 17, 18, 19, 20 -pentanor-prosta-5,13 -dienoic acid sodium salt], is a synthetic, chemically stable analogue of PGI2 that has been specifically designed to enhance cytoprotective actions, while minimizing unwanted hemodynamic effects. Thus, taprostene has a profile of activity including prevention of aggregation in cat platelets15 at concentrations that are much lower than that required to produce significant vasodilator activity in rabbit aortic rings. In addition to antiaggregatory and cytoprotective effects15-17 in circulatory shock, taprostene exerts beneficial effects in acute inflammatory states18 and in rat models of myocardial hypoxia and permanent ischemia. 19 The purposes of this study were 1) to investigate the cardioprotective effects of exogenously infused taprostene (100 ng/kg/min) in a model of acute myocardial ischemia followed by reperfusion, and 2) to elaborate the mechanism(s) by which taprostene may achieve any cardioprotective effects.
Materials and Methods Adult male cats (2.5-3.5 kg) were anesthetized with sodium pentobarbital (35 mg/kg body wt i.v.). An intratracheal cannula was inserted through a midline incision and all cats were placed on intermittent-positive-pressure ventilation (Harvard small animal respirator, Harvard Apparatus, South Natick, Massachusetts). Polyethylene catheters were inserted into the right external jugular and the right femoral veins. The right femoral artery was also cannulated and connected to a Statham P23AC pressure transducer (Gould, Cleveland, Ohio) to record arterial blood pressure. A midline thoracotomy was performed, and the heart was exposed after opening the pericardium. A silk ligature (2-0) was placed around the left anterior descending coronary artery (LAD) 10 to 12 mm from its origin. Arterial blood pressure was continuously recorded on an oscillographic recorder (model 7, Grass Instruments, Quincy, Massachusetts). Heart rates and ST segment elevations were obtained by ECG recording from lead II every 20 minutes. The pressure-rate index was calculated as the product of mean arterial blood pressure and heart rate divided by 1,000 and was used as an approximation of myocardial oxygen demand. 20 
Experimental Protocol
Thirty minutes after completion of all surgical procedures, myocardial ischemia was produced by ligating the LAD. This was designated as time zero. After 1.5 hours of ischemia, the LAD ligature was untied and the ischemic myocardium was reperfused for an additional 4.5 hours, resulting in a total experimental time of 6 hours. Thirty minutes after coronary ligation, taprostene (pH 9.0) (Grunenthal GmbH, Aachen, FRG) or its vehicle (0.9% NaCI, pH 9.0) was infused intravenously at a rate of 100 ng/kg/min until the end of the experiment (i.e., for 5.5 hours). A variety of infusion rates of taprostene from 50 to 200 ng/kg/min were initially used to obtain an infusion rate that produced minimal hemodynamic (i.e., vasodilator) effects but still exerted cardioprotective effects. The optimal rate of taprostene infusion was determined to be 100 ng/kg/min. Cats infused with the vehicle received 1.2 ml/hr of 0.9% NaCl over the same time period. Four experimental groups were studied: sham myocardial ischemia (MI)+vehicle (n=4), sham MI+taprostene (n=7), MI+vehicle (n=6), and MI+taprostene (n=7). The sham MI cats were subjected to all procedures except that the ligature around the LAD was not tightened.
Blood Sampling
Arterial blood samples (2 ml) were drawn immediately before ligation and hourly thereafter. The blood samples were collected in tubes containing 200 IU heparin sodium. Samples were centrifuged at 2,500g and 40 C for 20 minutes. The plasma was drawn off and analyzed spectrophotometrically for creatine kinase (CK) activity according to the method of Rosalki,21 and for protein concentration by the biuret method.22 Plasma CK specific activity was expressed as international units per milligram protein times 1,000.
Myocardial Tissue Analysis
At the end of the 6-hour experimental period, the ligature around the LAD was retightened to completely occlude the vessel. At that time, 30 ml of 0.5% Evans blue was injected into the left atrium to stain that area of the myocardium perfused by the patent coronary arteries. The area at risk was thus determined by negative staining. The heart was rapidly excised, and the right ventricle and great vessels were removed. The left ventricle was then sliced parallel to the atrioventricular groove in 3-mm-thick sections. The unstained portion of the myocardium (i.e., the total area at risk) was separated from the rest of the myocardium (i.e., the area not at risk). That portion of the myocardium at risk was again sliced into thin slices (i.e., 1 12 ,500g at 40 C. The supernatants were then collected and reacted with 0.167 mg/ml o-dianisidine dihydrochloride (Sigma Chemical) and 0.0005% H202 in 50 mM phosphate buffer at a pH of 6. The change in absorbance was measured spectrophotometrically at 460 nm. One unit of MPO activity is defined as that quantity of enzyme degrading 1 gmol H202/min at 250 C.
Artery Ring Preparation
Segments of both the LAD and the left circumflex coronary artery (LCX) were excised at the end of the experiment just after Evans blue staining, which was used to demarcate the area at risk from the area not at risk. These segments were then dissected free of connective tissue, cut transversely into rings, and connected to force transducers in 20-ml chambers filled with Krebs-Henseleit solution of the following millimolar composition: NaCl 120, glucose 10, NaHCO3 125, KCI 4.74, KH2S04 1.19, EDTA 0.016, and CaCl2 2.5. The Krebs-Henseleit solution was bubbled with 95% 02-5% CO2 and temperature was maintained at a constant 370 C by means of a circulating water bath surrounding the chamber. Resting force was set at 0.5 g, and the rings were allowed to equilibrate for 90-120 minutes. This resting force was that force on the small artery rings at which a maximal response to U46619 could be obtained. At that time, the rings were precontracted with 30 nM U46619 (9,11-methanoepoxy-prostaglandin H2, The Upjohn Company, Kalamazoo, Michigan), a thromboxane mimetic. The rings were then subjected to sequential additions of acetylcholine (ACh) 0.01-10 nM and acidified sodium nitrite (NaNO2, pH 2.0) 0.1-100 ,lM. ACh produces endothelium-dependent smooth muscle relaxation, whereas acidified NaNO2 produces direct smooth muscle relaxation and thus is not endothelium dependent. Additional experiments were performed in cat thoracic aortic rings precontracted with 2 gtM norepinephrine, and then taprostene at 1 ng/ml to 1 ,ug/ml was tested for its ability to relax the aortic rings.
Data Analysis
All values in the text and figures are presented as mean+ SEM of n independent experiments. The data were analyzed by using analysis of variance with repeated measures when appropriate. Differences between specific means were tested by post hoc analysis using Student's t test with the Bonferroni correction for multiple comparisons. Values of p<0.05 were considered to be statistically significant. Time (Hours) FIGURE 1. Pressure-rate index expressed as mm Hgx (beats! min)/1000 sampled hourly during the 6-hour myocardial ischemia (MI) followed by reperfusion. All Figure 3) . Thus, the taprostene treatment exerted a significant reduction in ischemic damage in the cat after ischemia and reperfusion. One of the mechanisms thought to be responsible for reperfusion injury is adherence of neutrophils to the vascular endothelium of the ischemic region. MPO activity is specific for neutrophils25 and can therefore be used as a marker for neutrophil accumulation in the heart. Figure 4 Figure 5 illustrates typical recordings of developed force obtained from cat coronary arterial ring preparations. These data were obtained from coronary rings isolated from a cat subjected to myocardial ischemia and reperfusion and administered only the vehicle (i.e., 0.9% NaCI). The upper pair of tracings illustrates the response of coronary rings taken from the left anterior descending branch of the left coronary artery, which was subjected to ischemia and reperfusion. The lower pair of tracings illustrates the response of coronary rings taken from the LCX branch, which was not subjected to ischemia and reperfusion. Recordings on the left side of the figure illustrate the response to ACh, which is an endothelium-dependent vasodilator. Recordings on the right side of the figure illustrate the response to acidified NaNO2, which is an endothelium-independent vasodilator. The upper left recording clearly shows an impaired ability to respond to ACh in the LAD rings, while the tracing in the upper right shows that the endothelium-independent vasodilator, acidified NaNO2, is capable of producing a full vasodilation in the same ring. These data indicate that a functional deficit exists in the endothelium because the vascular smooth muscle responds normally to both the vasoconstrictor U46619 and the endothelium-independent dilator, acidified NaNO2. The lower pair of recordings illustrates normal relaxation in response to both ACh and acidified NaNO2 in the LCX rings, which were used as a control. Figure 7 summarizes the responses of U46619 precontracted cat coronary artery rings to acidified NaNO2, an endothelium-independent vasodilator, in all three groups of cats studied. These are the same rings as those tested with ACh. The left panel illustrates the percentage of relaxation produced in response to acidified NaNO2 in coronary artery rings obtained from the LAD. There were no significant differences among the groups in the ability of these coronary artery rings to relax completely (i.e., not significantly different from 100%) in response to acidified NaNO2. The panel on the right illustrates the percentage of relaxation produced in response to acidified NaNO2 in coronary artery rings taken from the LCX. There were no significant differences among any of the groups in the ability of these coronary artery rings to relax completely in response to acidified NaNO2. These results indicate a normal vasorelaxant ability of coronary vascular smooth muscle in both the experimental and control coronary arteries to respond to direct (i.e., non-endothelium-dependent) dilators.
Discussion
The data presented in this study clearly show that taprostene exerts significant cardioprotective effects in the cat myocardium subjected to ischemia and reperfusion. LAD occlusion for 1.5 hours resulted in an ST segment elevation, indicating a significant insult to ischemic cardiac tissue. Other signs of ischemia were the dark, cyanotic color of the epicardium distal to the ligation and subsequent bulging in this area of the left ventricle.
We obtained several lines of evidence including anatomic, biochemical, and physiological data that taprostene exerts a cardioprotective effect in ischemia and reperfusion. First, plasma CK activities, indicative of the severity of ischemic injury to the myocardium, were significantly lower in cats treated with taprostene than those cats receiving only the vehicle. The degree of protection observed in the MI+taprostene group was so effective that plasma CK activities were not significantly different from sham MI cats at any time during the 6-hour observation period. Thus, taprostene prevented the loss of CK from ischemic tissue during the first 6 hours after myocardial ischemia, suggesting a significant cardioprotective effect.
Second, analysis of myocardial tissue clearly indicated that the ischemia groups were exposed to a comparable degree of myocardial jeopardy as a result of LAD occlusion. However, a relatively large proportion of the area at risk became necrotic myocardial tissue in untreated MI cats. Taprostene There are a variety of possible mechanisms by which taprostene could provide cardioprotection including 1) hemodynamic effects such as a direct vasodilator effect on vascular smooth muscle and a reduced cardiac afterload, 2) cytoprotection of vascular endothelial cells, 3) prevention of activation of neutrophils thus inhibiting their release of mediators, and 4) a combination of several of these mechanisms.
Both PGI2 and taprostene have been shown to have a direct vasodilator effect on vascular smooth muscle by activation of adenylate cyclase, leading to the production of cyclic AMP, thus inhibiting the contractile process and inducing relaxation.2,15 However, taprostene has been designed specifically to minimize vasodilation at concentrations that produce cytoprotective effects. In six cat aortic rings, taprostene at concentrations of 1-100 ng/ml failed to exert any vasorelaxant effect. At 300 ng/ml, taprostene relaxed the vascular rings 34±-3%. The EC50 for taprostene in this preparation was calculated to be 520 ng/ml, a value 26 times that of its antiplatelet aggregatory effect in cat platelet-rich plasma.15 In this study, the dose of taprostene used was specifically chosen to avoid systemic vasodilation, and indeed, no evidence of systemic vasodilation was observed. Therefore, taprostene probably does not protect the ischemic myocardium by reducing myocardial oxygen demand.
Ischemia and reperfusion lead to release of vasoactive mediators that may be involved in functional alterations and damage to the endothelium. Among these are products of cyclooxygenase and lipoxygenase metabolism of arachidonic acid. These products and others have been shown to aggregate platelets, constrict coronary vascular smooth muscle (e.g., thromboxane A2, leukotriene D4)31 ' and recruit neutrophils (e.g., leukotriene B4). Damage or loss of endothelial cells would allow circulating mediators direct access to the underlying smooth muscle cells where they could produce effects on vascular tone or inhibit smooth muscle cell function. Data from the coronary artery ring preparations clearly show that taprostene contributes to a functional preservation of the endothelium in terms of its ability to respond to endothelium-dependent vasodilators.
Taprostene exerts antiplatelet activity in a variety of species15,34,35 and also has platelet disaggregatory activity. 2 The endothelium normally provides a nonthrombogenic surface that prevents platelets from aggregating and adhering when the coagulation cascade is activated, thus protecting the underlying myocytes. The interactions of taprostene with other vasoactive substances has not yet been fully explored. However, it has been demonstrated that nitric oxide, the most probable identity of endothelium-derived relaxing factor and PGI2 have synergistic effects in the inhibition of platelet aggregation. Endothelial cells are known to produce endothelium-derived relaxing factor and PGI1 in response to thrombin and other products released by aggregating platelets. It is evident from the data on coronary artery rings that taprostene protected against endothelial damage produced acutely in myocardial ischemia and reperfusion, thus maintaining an intact thromboresistant surface.
Neutrophils and products of neutrophils have been associated with a component of damage induced in myocardial ischemia and reperfusion.36,37 It is known that the complement system is activated in ischemic tissue,38 producing factors that cause neutrophils to migrate along chemotactic gradients to areas of injury and damage, adhere to endothelial cells, and ultimately infiltrate damaged and necrotic areas. Significant reductions in myocardial damage have been accomplished after experimental coronary occlusion by inactivation of the complement system.39 Moreover, oxygen-derived free radicals produced by neutrophils26,40,41 are also thought to play a role in myocardial cell injury. We have shown that taprostene prevents the accumulation and adherence of neutrophils both in the area at risk and in the necrotic zone, thus limiting the opportunities for microvascular plugging by neutrophil aggregates and reducing the opportunity for neutrophilinduced damage by toxic product release. These effects occurred despite any effect of taprostene on the actual size of the area at risk. In this regard, cytokines (e.g., tumor necrosis factor and interleukin-1,() released from neutrophils have recently been found to induce endothelial cell expression of a neutrophil chemotactic factor.42 Thus, there is an intimate interrelationship between activated neutrophils and endothelial cells, which taprostene may inhibit. Further investigation is necessary to clarify these interrelationships.
